When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature

Schizophrenia Research

Volumn 134, Issue 2-3, 2012, Pages 180-186

  Manu, Peter ^a,b,c   Sarpal, Deepak ^a   Muir, Owen ^a   Kane, John M ^a,b,c   Correll, Christoph U ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b HOFSTRA UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Agranulocytosis; Clozapine; Myocarditis; Neuroleptic malignant syndrome; Neutropenia; Rechallenge

Indexed keywords

ASCORBIC ACID; CLOMIPRAMINE; CLOZAPINE; FLUPENTIXOL DECANOATE; GRANULOCYTE COLONY STIMULATING FACTOR; HALOPERIDOL DECANOATE; LITHIUM; OLANZAPINE;

ADD ON THERAPY; AGRANULOCYTOSIS; BLOOD DYSCRASIA; DEATH; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG RECHALLENGE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PERICARDITIS; PRIORITY JOURNAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DATABASES, BIBLIOGRAPHIC; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; YOUNG ADULT;

EID: 84856254331     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.10.014     Document Type: Review

References (64)

1. Alvir J.M., Lieberman J.A., Safferman A.Z., Schwimmer J.L., Schaaf J.A. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N. Engl. J. Med. 1993, 329(3):162-167.
2. Anderson E.S., Powers P.S. Neuroleptic malignant syndrome associated with clozapine use. J. Clin. Psychiatry 1991, 52(3):102-104.
3. Arias S.A., Cohen P., Kwon J.S. Clozapine-induced lymphocytic alveolitis. Am. J. Psychiatry 2011, 168(2):210-211.
4. Athanasiou M.C., Dettling M., Cascorbi I., Mosyagin I., Salisbury B.A., Pierz K.A., Zou W., Whalen H., Malhotra A.K., Lencz T., Gerson S.L., Kane J.M., Reed C.R. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J. Clin. Psychiatry 2011, 72(4):458-463.
5. Au A.F., Luthra V., Stern R. Clozapine-induced acute interstitial nephritis. Am. J. Psychiatry 2004, 161(8):501.
6. Bayard J.M., Descamps O.S., Evrard S., Dumonceau J.M., Servais L., Zingir Z., Adams S., Dassy V., Stillemans E., Seutin A., Titeca P., Titeca J. Case report: acute pancreatitis induced by clozapine. Acta Gastroenterol. Belg. 2005, 68(1):92-94.
7. Blieden N., Flinders S., Hawkins K., Reid M., Alphs L.D., Arfken C.L. Health status and health care costs for publicly funded patients with schizophrenia started on clozapine. Psychiatr. Serv. 1998, 49(12):1590-1593.
8. Bray A. Ethnic neutropenia and clozapine. Aust. N. Z. J. Psychiatry 2008, 42(4):342-345.
9. Bray A., Reid R. Successful clozapine rechallenge after acute myocarditis. Aust. N. Z. J. Psychiatry 2011, 45(1):90.
10. Chang A., Krygier D.S., Chatur N., Yoshida E.M. Clozapine-induced fatal fulminant hepatic failure: a case report. Can. J. Gastroenterol. 2009, 23(5):376-378.
11. Chatterton R., Cardy S., Schramm T.M. Neuroleptic malignant syndrome and clozapine monotherapy. Aust. N. Z. J. Psychiatry 1996, 30(5):692-693.
12. Chengappa K.N., Gopalani A., Haught M.K., McChesney K., Baker R.W., Schooler N.R. The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF). Psychopharmacol. Bull. 1996, 32(1):111-121.
13. Cohen D., Correll C.U. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors and screening need. J. Clin. Psychiatry 2009, 70(5):765-766.
14. Crews M.P., Dhillon G.S., MacCabe J.H. Clozapine rechallenge following clozapine-induced pericarditis. J. Clin. Psychiatry 2010, 71(7):959-961.
15. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist. Psychiatry 2007, 18(1):39-60.
16. DasGupta K., Young A. Clozapine-induced neuroleptic malignant syndrome. J. Clin. Psychiatry 1991, 52(3):105-107.
17. Davies L.M., Barnes T.R., Jones P.B., Lewis S., Gaughran F., Hayhurst K., Markwick A., Lloyd H., Team C.U.T.L.A.S.S. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health 2008, 11(4):549-562.
18. Dunk L.R., Annan L.J., Andrews C.D. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br. J. Psychiatry 2006, 188:255-263.
19. Eseonu C., Carlson J. Clozapine rechallenge in refractory schizophrenia. Am. J. Psychiatry 2010, 167(5):602-603.
20. Essali A., Al-Haj Haasan N., Li C., Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst. Rev. 2009, 21(1):CD000059. (Jan).
21. Frankenburg F.R., Stormberg D., Gerson S.L. Unsuccessful reexposure to clozapine. J. Clin. Psychopharmacol. 1994, 14(6):428-429.
22. Gandelman-Marton R., Theitler J., Klein C., Rabey J.M. Phenytoin intoxication in a clozapine-related prolonged seizure. J. Emerg. Med. 2008, 35(4):407-409.
23. Gerbino-Rosen G., Roofeh D., Tompkins D.A., Feryo D., Nusser L., Kranzler H., Napolitano B., Frederickson A., Henderson I., Rhinewine J., Kumra S. Hematological adverse events in clozapine-treated children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 2005, 44(10):1024-1031.
24. Gerson S.L. G-CSF and the management of clozapine-induced agranulocytosis. J. Clin. Psychiatry 1994, 55:139-142. (Suppl B).
25. Ghaznavi S., Nakic M., Rao P., Hu J., Brewer J.A., Hannestad J., Bhagwagar Z. Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. Am. J. Psychiatry 2008, 165(7):813-818.
26. Goates M.G., Escobar J.I. An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge. J. Clin. Psychopharmacol. 1992, 12(2):139-140.
27. Grohmann R., Schmidt L.G., Spiess-Kiefer C., Rüther E. Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMUP program. Psychopharmacology (Berl) 1989, 99:109-112. (Suppl S).
28. Huang T.L. Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge. Chang Gung Med. J. 2001, 24(8):522-525.
29. Imbarlina M.J., Sarkar S., Marwah S., Parepally H., Johnston P.R., Brar J.S., Chengappa K.N. Leukopenia in clozapine treated patients may be induced by other drugs: a case series. Eur. Psychiatry 2004, 19(8):506-509.
30. Jayathilake I., Singh A.K. Clozapine rechallenge after myocarditis. Australas. Psychiatry 2009, 17(5):421-422.
31. Joffe G., Eskelinen S., Sailas E. Add-on filgrastim during clozapine rechallenge in patients with a history of clozapine-related granulocytopenia/agranulocytosis. Am. J. Psychiatry 2009, 166(2):236.
32. Juul Povlsen U., Noring U., Fog R., Gerlach J. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr. Scand. 1985, 71(2):176-185.
33. Kanaan R.A., Kerwin R.W. Lithium and clozapine rechallenge: a retrospective case analysis. J. Clin. Psychiatry 2006, 67(5):756-760.
34. Kane J.M., Correll C.U. Past and present progress in the pharmacologic treatment of schizophrenia. J. Clin. Psychiatry 2010, 79(9):1115-1124.
35. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45(9):789-796.
36. Kelly D.L., Kreyenbuhl J., Dixon L., Love R.C., Medoff D., Conley R.R. Clozapine underutilization and discontinuation in African-Americans due to leucopenia. Schizophr. Bull. 2007, 33(5):1221-1225.
37. Lee J.W. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J. Clin. Psychopharmacol. 2010, 30(1):3-10.
38. Lewis S.W., Barnes T.R., Davies L., Murray R.M., Dunn G., Hayhurst K.P., Markwick A., Lloyd H., Jones P.B. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 2006, 32(4):715-723.
39. Mathewson K.A., Lindenmayer J.P. Clozapine and granulocyte colony-stimulating factor: potential for long-term combination treatment for clozapine-induced neutropenia. J. Clin. Psychopharmacol. 2007, 27(6):714-715.
40. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K., Investigators C.A.T.I.E. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163(4):600-610.
41. McKnight C., Guirgis H., Votolato N. Clozapine rechallenge after excluding the high-risk clozapine-induced agranulocytosis genotype of HLA-DQB1 6672G>C. Am. J. Psychiatry 2011, 168(10):1120.
42. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 2003, 60(1):82-91. International Suicide Prevention Trial Study Group.
43. Merrill D.B., Dec G.W., Goff D.C. Adverse cardiac effects associated with clozapine. J. Clin. Psychopharmacol. 2005, 25(1):32-41.
44. Micromedex® Healthcare Series [intranet database]. Version 2.0. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc.
45. Miller D.D., Sharafuddin M.J., Kathol R.G. A case of clozapine-induced neuroleptic malignant syndrome. J. Clin. Psychiatry 1991, 52(3):99-101.
46. Pelizza L., Melegari M. Clozapine-induced microscopic colitis: a case report and review of the literature. J. Clin. Psychopharmacol. 2007, 27(6):571-574.
47. Pieroni M., Cavallaro R., Chimenti C., Smeraldi E., Frustaci A. Clozapine-induced hypersensitivity myocarditis. Chest 2004, 126(5):1703-1705.
48. Rami A.F., Barkan D., Mevorach D., Leitersdorf E., Caraco Y. Clozapine-induced systemic lupus erythematosus. Ann. Pharmacother. 2006, 40(5):983-985.
49. Rathore S., Masani N.D., Callaghan P.O. Clozapine-induced effuso-constrictive pericarditis. Case report and review of the literature. Cardiology 2007, 108(3):183-185.
50. Reid P. Clozapine rechallenge after myocarditis. Aust. N. Z. J. Psychiatry 2001, 35(2):249.
51. Reinders J., Parsonage W., Lange D., Potter J.M., Plever S. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust. N. Z. J. Psychiatry 2004, 38(11-12):915-922.
52. Safferman A.Z., Lieberman J.A., Alvir J.M. Rechallenge in clozapine-induced agranulocytosis. Lancet 1992, 339(8804):1296-1297.
53. Safferman A.Z., Lieberman J.A., Zeman D., Szymanski S., Pisciotta A.V., Rai K. Unrelated agranulocytosis in a patient taking clozapine. J. Clin. Psychopharmacol. 1993, 13(3):218-219.
54. Silvestrini C., Arcangeli T., Biondi M., Pancheri P. A second trial of clozapine in a case of granulocytopenia. Hum. Psychopharmacol. 2000, 15(4):275-279.
55. Small J.G., Weber M.C., Klapper M.H., Kellams J.J. Rechallenge of late-onset neutropenia with clozapine. J. Clin. Psychopharmacol. 2005, 25(2):185-186.
56. Sperner-Unterweger B., Czeipek I., Gaggl S., Geissler D., Spiel G., Fleischhacker W.W. Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine. Br. J. Psychiatry 1998, 172:82-84.
57. Stille G., Hippius H. Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmacopsychiatry 1971, 4:182-191.
58. Szarek B.L., Goethe J.W., Pentz P.G. Unsuccessful reexposure to clozapine. J. Clin. Psychopharmacol. 1997, 17(1):71-73.
59. Tourian L., Margolese H.C. Late-onset agranulocytosis in a patient treated with clozapine and lamotrigine. J. Clin. Psychopharmacol. 2011, 31(5):665-667.
60. Tsai G., Crisostomo G., Rosenblatt M.L., Stern T.A. Neuroleptic malignant syndrome associated with clozapine treatment. Ann. Clin. Psychiatry 1995, 7(2):91-95.
61. Tschen A.C., Rieder M.J., Oyewumi L.K., Freeman D.J. The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clin. Pharmacol. Ther. 1997, 65(5):526-532.
62. Whiskey E., Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 2007, 21(1):25-35.
63. Wu S.Y., Liu C.C., Hsieh M.H. Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(4):1089-1090.
64. Yang L., Wang K., Chen J., Jegga A.G., Luo H., Shi L., Wan C., Guo X., Qin S., He G., Feng G., He L. Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome; clozapine-induced agranulocytosis as a case study. PLoS Comput. Biol. 2011, 7(3):e1002016.